AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25172200 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen sponges (GCS)
Number of subjects: 291
Study 25172200 — intervention group
Group type: COMPARATOR
Intervention: Collagen sponge without antibiotics
Number of subjects: 291
Study 25172200 — intervention group
Group type: COMPARATOR
Intervention: No sponge (control group)
Number of subjects: 291
Study 24052204 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes intervention with community health workers (CHWs)
Number of subjects: 104
Study 21453895 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP monitoring (group A)
Number of subjects: 170
Study 21453895 — intervention group
Group type: COMPARATOR
Intervention: Judgment of clinical signs (group B)
Number of subjects: 170
Study 18281394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay educator
Number of subjects: 567
Study 18281394 — intervention group
Group type: COMPARATOR
Intervention: Practice nurse
Number of subjects: 567
Study 18281394 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 567
Study 16585864 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine block of the recurrent laryngeal nerve
Number of subjects: 21
Study 11907654 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid fat infusion over 6 h (rFI)
Number of subjects: 18
Study 11907654 — intervention group
Group type: COMPARATOR
Intervention: Slow fat infusion over 24 h (sFI)
Number of subjects: 18
Study 10208786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump therapy
Number of subjects: 238
Study 10208786 — intervention group
Group type: COMPARATOR
Intervention: No intra-aortic balloon pump therapy
Number of subjects: 238
Study 9497628 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid mouthwash
Number of subjects: 24
Study 9497628 — intervention group
Group type: COMPARATOR
Intervention: systemic tranexamic acid (control)
Number of subjects: 24
Study 2365119 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin or Mezlocillin (single-dose prophylaxis)
Number of subjects: 48
Study 2365119 — intervention group
Group type: COMPARATOR
Intervention: Radical vulvectomy (control group)
Number of subjects: 48
Study 330077 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol (20, 40, and 60 mg daily)
Number of subjects: 18
Study 330077 — intervention group
Group type: COMPARATOR
Intervention: propranolol (0.2 mg/kg intravenously)
Number of subjects: 18
Study 330077 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 7245774 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg slow-release allopurinol
Number of subjects: 0
Study 7245774 — intervention group
Group type: COMPARATOR
Intervention: Normal release allopurinol
Number of subjects: 0
Study 7245774 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release allopurinol
Number of subjects: 0
Study 29370028 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia (<150.000/mm) in cases with Type I ROP
Number of subjects: 81
Study 29370028 — intervention group
Group type: COMPARATOR
Intervention: No thrombocytopenia in controls
Number of subjects: 81
Study 29370028 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia and thrombocytopenia
Number of subjects: 81
Study 29370028 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia ratio
Number of subjects: 81
Study 29370028 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia 1 week before intervention
Number of subjects: 81
Study 29370028 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion ratio
Number of subjects: 81
Study 29474280 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of oral phenazopyridine
Number of subjects: 88
Study 29474280 — intervention group
Group type: COMPARATOR
Intervention: No phenazopyridine (Control)
Number of subjects: 88
Study 27209341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic proximal tubal occlusion by intratubal devices
Number of subjects: 85
Study 27209341 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic salpingectomy
Number of subjects: 85
Study 24474086 — intervention group
Group type: EXPERIMENTAL
Intervention: DIC patients with elevated plasma CL-K1 levels
Number of subjects: 659
Study 24474086 — intervention group
Group type: COMPARATOR
Intervention: Non-DIC patients
Number of subjects: 659
Study 24474086 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 659
Study 22412865 — intervention group
Group type: EXPERIMENTAL
Intervention: Late exposure group (LEG) - Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months
Number of subjects: 349
Study 22412865 — intervention group
Group type: EXPERIMENTAL
Intervention: Early exposure group (EEG) - Placebo from 2.5-4.5 months and SP+AS from 5.5-9.5 months
Number of subjects: 349
Study 22412865 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - Placebo from 2.5-9.5 months
Number of subjects: 349
Study 20631460 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG) applied 4 g, 4 times daily
Number of subjects: 420
Study 20631460 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control) applied 4 g, 4 times daily
Number of subjects: 420
Study 20631460 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG)
Number of subjects: 420
Study 20631460 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 420
Study 17397001 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon-alpha 2a/ribavirin therapy
Number of subjects: 31
Study 15719490 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed at a dose of 2.5 mg/m(2) intravenously (i.v), once every 3 weeks, for two doses, combined with standard radiotherapy of 70 Gy over 7 weeks.
Number of subjects: 17
Study 15719490 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed at a dose of 2.5 mg/m(2) given twice 3 weeks apart, combined with 70 Gy of radiotherapy.
Number of subjects: 17
Study 12112183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 2 x 240 mg
Number of subjects: 42
Study 12112183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10091405 — intervention group
Group type: EXPERIMENTAL
Intervention: (TA)7/(TA)7 genotype
Number of subjects: 60
Study 10091405 — intervention group
Group type: COMPARATOR
Intervention: (TA)7/(TA)6 or (TA)6/(TA)6 genotypes
Number of subjects: 60
Study 7749498 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intensive treatment and patient education with the distress reduction program
Number of subjects: 23
Study 7749498 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive treatment and patient education without the distress reduction program
Number of subjects: 23
Study 2178909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0
Study 373084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 600 mg daily
Number of subjects: 60
Study 373084 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg daily
Number of subjects: 60
Study 373084 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1,500 mg daily
Number of subjects: 60
Study 30551223 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (Continuous Positive Airway Pressure)
Number of subjects: 220
Study 30551223 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 220
Study 28009472 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg for 1 month (TP1)
Number of subjects: 44
Study 28009472 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg (TP2)
Number of subjects: 44
Study 28009472 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg (TP1)
Number of subjects: 44
Study 28009472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TP2)
Number of subjects: 44
Study 25629710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app providing personalized sun protection advice
Number of subjects: 604
Study 24651895 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses-based 3D monitor
Number of subjects: 48
Study 24651895 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror-based 3D display
Number of subjects: 48
Study 24651895 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D displays (general)
Number of subjects: 48
Study 24651895 — intervention group
Group type: COMPARATOR
Intervention: 2D HD display
Number of subjects: 48
Study 24651895 — intervention group
Group type: COMPARATOR
Intervention: Autostereoscopic display
Number of subjects: 48
Study 24651895 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D and 2D displays
Number of subjects: 48
Study 24651895 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D display (general)
Number of subjects: 48
Study 22846147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) at 1 day before PPV
Number of subjects: 30
Study 22846147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) at 7 days before PPV
Number of subjects: 30
Study 22846147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 30
Study 19753648 — intervention group
Group type: COMPARATOR
Intervention: G-CSF (5 microg/kg/day for 5-7 days)
Number of subjects: 30
Study 19753648 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple group (GM-CSF 10 microg/kg/day on 1st and 2nd day, G-CSF 5 microg/kg/day for 5-7 days, and darbepoetin-alpha 40 mg on 1st day)
Number of subjects: 30
Study 19753648 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 30
Study 19753648 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple group
Number of subjects: 30
Study 17499604 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily) + Esomeprazole (20 mg twice daily)
Number of subjects: 441
Study 17499604 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (200 mg twice daily) + Placebo
Number of subjects: 441
Study 15179107 — intervention group
Group type: EXPERIMENTAL
Intervention: Health screening, written feedback, and an optional follow-up visit with the general practitioner
Number of subjects: 1507
Study 15179107 — intervention group
Group type: EXPERIMENTAL
Intervention: Health screening, written feedback, and a planned 45-min follow-up visit with the general practitioner
Number of subjects: 1507
Study 15179107 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 1507
Study 12468168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine ointment
Number of subjects: 200
Study 12468168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12468168 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor lacerations
Number of subjects: 200
Study 9655734 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (75 mg vitamin E, 650 mg vitamin C, 15 mg beta carotene)
Number of subjects: 47
Study 9655734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 7649323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant alpha‐interferon treatment (once a week for 8 weeks)
Number of subjects: 83
Study 7649323 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant interferon treatment (control group)
Number of subjects: 83
Study 2501765 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin bolus (n = 24)
Number of subjects: 38
Study 2501765 — intervention group
Group type: COMPARATOR
Intervention: No insulin bolus (n = 32)
Number of subjects: 38
Study 588388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentolinium tartrate (Ansolysen) in doses of 10-15 mg
Number of subjects: 0
Study 588388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29688121 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (three doses, first dose at 0-5 days after birth)
Number of subjects: 96
Study 29688121 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (three doses, first dose at about 8 weeks after birth)
Number of subjects: 96
Study 29688121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo schedule)
Number of subjects: 96
Study 28729014 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol bladder distention
Number of subjects: 130
Study 28729014 — intervention group
Group type: COMPARATOR
Intervention: Oral phenazopyridine
Number of subjects: 130
Study 28729014 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sodium fluorescein
Number of subjects: 130
Study 28729014 — intervention group
Group type: COMPARATOR
Intervention: Normal saline bladder distention
Number of subjects: 130
Study 28729014 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 130
Study 26041585 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 or 50 mg, depending on renal function)
Number of subjects: 388
Study 26041585 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (titrated doses)
Number of subjects: 388
Study 23337378 — intervention group
Group type: EXPERIMENTAL
Intervention: MGuard™ stent (MGS)
Number of subjects: 40
Study 23337378 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 40
Study 22141471 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical visualisation software for ankle-foot orthosis tuning
Number of subjects: 70
Study 22141471 — intervention group
Group type: COMPARATOR
Intervention: Standard care (tuning using observation alone)
Number of subjects: 70
Study 18328440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling for regular homemade food
Number of subjects: 60
Study 18328440 — intervention group
Group type: COMPARATOR
Intervention: Commercial MCT‐enriched dietary supplements
Number of subjects: 60
Study 16556409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule
Number of subjects: 93
Study 16556409 — intervention group
Group type: COMPARATOR
Intervention: Heluoshugan capsule
Number of subjects: 93
Study 14630567 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP860 (25 mg/kg)
Number of subjects: 145
Study 14630567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 11550107 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic NSAID intake (n = 861)
Number of subjects: 3743
Study 11550107 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (n = 2882)
Number of subjects: 3743
Study 11550107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3743
Study 8899319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain
Number of subjects: 10
Study 8899319 — intervention group
Group type: COMPARATOR
Intervention: Control (no Ukrain)
Number of subjects: 10
Study 1511192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry group (fluid administration: 50, 60, 70, 80, 90, 100 and 120 ml/kg/day during the first week and 150 ml/kg/day until aged four weeks)
Number of subjects: 100
Study 1511192 — intervention group
Group type: COMPARATOR
Intervention: Control group (fluid administration: 80, 100, 120 and 150 ml/kg/day during the first week and 200 ml/kg afterwards)
Number of subjects: 100
Study 1511192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry group
Number of subjects: 100
Study 1511192 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 6844664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 20
Study 6844664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6844664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 20
Study 30160627 — intervention group
Group type: COMPARATOR
Intervention: LOW (9 weekly sets, 1 session per week)
Number of subjects: 49
Study 30160627 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD (18 weekly sets, 2 sessions per week)
Number of subjects: 49
Study 30160627 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (27 weekly sets, 2 sessions per week)
Number of subjects: 49
Study 29979618 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA decision support system (DSS)
Number of subjects: 24
Study 27927145 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock music
Number of subjects: 352
Study 27927145 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 352
Study 27927145 — intervention group
Group type: COMPARATOR
Intervention: Sound of an operating theatre
Number of subjects: 352
Study 25844686 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit-based resistance training (CRT) for 8 weeks
Number of subjects: 18
Study 25844686 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control group (CON)
Number of subjects: 18
Study 23547239 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker combinations centered on insulin‐like growth factor acid labile subunit
Number of subjects: 300
Study 23547239 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 validated models combining various biomarkers
Number of subjects: 300
Study 20970976 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0633 100 mg
Number of subjects: 266
Study 20970976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 18713501 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for 6 months, offered to 568 subjects, with 565 accepting.
Number of subjects: 1932
Study 18713501 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) with counseling and monthly follow-up.
Number of subjects: 1932
Study 18713501 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-completion reasons for 72 subjects: 24 (33%) physician-initiated due to active TB or side effects, 42 (58%) patient-initiated due to self-cessation or loss to follow-up, and 6 (8%) due to death unrelated to IPT.
Number of subjects: 1932
Study 16540519 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 ml of alcohol gel
Number of subjects: 84
Study 16540519 — intervention group
Group type: COMPARATOR
Intervention: 1.75 ml of alcohol gel
Number of subjects: 84
Study 14571789 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alfa-2a (4.5 MU thrice weekly) and amantadine (200 mg daily)
Number of subjects: 30
Study 14571789 — intervention group
Group type: COMPARATOR
Intervention: Interferon therapy alone (4.5 MU thrice weekly)
Number of subjects: 30
Study 14571789 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alfa-2a and amantadine
Number of subjects: 30
Study 14571789 — intervention group
Group type: COMPARATOR
Intervention: Interferon therapy alone
Number of subjects: 30
Study 10736080 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (M)
Number of subjects: 46
Study 10736080 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine with butorphanol (M+B)
Number of subjects: 46
Study 10736080 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (B) 10 microg.kg‐1
Number of subjects: 46
Study 10736080 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (B) 1.2 microg.kg‐1.h‐1
Number of subjects: 46
Study 8726243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 5 mg/d
Number of subjects: 72
Study 8726243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/d
Number of subjects: 72
Study 8726243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/d
Number of subjects: 72
Study 8726243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (all doses)
Number of subjects: 72
Study 8726243 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 72
Study 8180540 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 274
Study 8180540 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital clinic care
Number of subjects: 274
Study 3034623 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium entry blockers PY 108‐068 (PY)
Number of subjects: 0
Study 3034623 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium entry blockers PN 200‐110 (PN)
Number of subjects: 0
Study 3034623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29448135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined child-CBT (Coping Power Program) and Parent Management Training (PMT)
Number of subjects: 120
Study 29448135 — intervention group
Group type: COMPARATOR
Intervention: Parent Management Training (PMT) only
Number of subjects: 120
Study 25794636 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Case Management with Problem-Solving Therapy (CM-PST)
Number of subjects: 171
Study 25794636 — intervention group
Group type: COMPARATOR
Intervention: Clinical Case Management (CM)
Number of subjects: 171
Study 25794636 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CM and CM-PST
Number of subjects: 171
Study 25794636 — intervention group
Group type: EXPERIMENTAL
Intervention: End of interventions to 12 weeks later
Number of subjects: 171
Study 26576808 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian balanced method electroacupuncture (BMEA) + Traditional Chinese Medicine Health Consultation (TCM HC)
Number of subjects: 30
Study 26576808 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Health Consultation (TCM HC)
Number of subjects: 30
Study 26576808 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 30
Study 25353642 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoropopliteal bypass
Number of subjects: 320
Study 25353642 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty and stenting
Number of subjects: 320
Study 21997893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Hospitalists (PH)
Number of subjects: 279
Study 20035187 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin
Number of subjects: 1135
Study 20035187 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/paclitaxel
Number of subjects: 1135
Study 20035187 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin
Number of subjects: 1135
Study 20035187 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with BM
Number of subjects: 1135